Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$83.78 USD

83.78
41,092

+1.45 (1.76%)

Updated Jun 28, 2024 03:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

by Zacks Equity Research

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

Ligand Pharmaceuticals (LGND) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $62.56, moving +0.94% from the previous trading session.

Ligand Pharmaceuticals (LGND) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $62.71, moving -1.45% from the previous trading session.

Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.

Ligand (LGND) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Ligand (LGND) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ligand Pharmaceuticals (LGND) Q2 Earnings Beat Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 86.84% and 5.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More

by Kinjel Shah

Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.

Ligand (LGND) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $66.56, marking a -1.35% move from the previous day.

Cadence Design and Ligand have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Cadence Design and Ligand have been highlighted as Zacks Bull and Bear of the Day.

Kevin Cook headshot

Bear of the Day: Ligand Pharmaceuticals (LGND)

by Kevin Cook

Ligand is an innovative Bio-Pharma M&A royalty-generator, but the model is volatile

Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $68.13, moving -0.92% from the previous trading session.

Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets

by Zacks Equity Research

Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.

Ligand Pharmaceuticals (LGND) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $68.76, moving +1.34% from the previous trading session.

Frequency (FREQ) Up 77% on Merger Deal With Korro Bio

by Zacks Equity Research

Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.

Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion

by Zacks Equity Research

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio

by Zacks Equity Research

For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.

Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill

by Zacks Equity Research

Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.

First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback

by Zacks Equity Research

Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.

Here's Why Investors Should Add Encompass Health (EHC) to Portfolio

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study

by Zacks Equity Research

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $69.49, moving -0.52% from the previous trading session.

Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval

by Zacks Equity Research

Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.